Executing the acquisition of all shares of Ayumi Pharmaceutical Holdings and issuing new shares through a third-party allotment to advance full subsidiarization and capital partnership. A significant capital policy involving approximately 4.7 billion yen of capital infusion and share transfer.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"Kabusikigaisha Ga Group","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-06-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/2160-20260605-01.pdf","jir_short_summary":"Executing the acquisition of all shares of Ayumi Pharmaceutical Holdings and issuing new shares through a third-party allotment to advance full subsidiarization and capital partnership. A significant capital policy involving approximately 4.7 billion yen of capital infusion and share transfer.","jir_summary":"### Overview of Capital Policy\nBased on a board resolution on June 5, 2026, the Company will acquire all shares of Ayumi Pharmaceutical Holdings for 44,776 million yen, advancing to full subsidiarization, and will issue new shares through a third-party allotment. The new shares will total 9,974,291, with an issue price of 2,684 yen per share. This will realize approximately 2.677 billion yen in capital raising, aiming to strengthen capital and expand business. The funds will be used for partial in-kind contribution of share transfer proceeds and are expected to contribute to future growth strategies.\n\n### Future Outlook and Impact on Shareholders\nThis capital policy aims to acquire Ayumi Pharmaceutical Holdings' commercial platform in Japan and accelerate overseas pipeline development and bio-similar expansion. Existing shareholders' ownership ratios will be diluted, but the objective is to enhance long-term corporate value and establish a stable earnings base. Fundraising will mainly be through third-party allotment, and it has been confirmed that there are no links to antisocial forces.","jir_financial_highlights":"Acquisition cost of shares in Ayumi Pharmaceutical Holdings: 44,776 million yen (Unknown)\nNumber of newly issued shares: 9,974,291 shares (Unknown)\nFundraising amount: 26,770,997,044 yen (Unknown)","jir_category":"","jir_hashtags":"#KabusikigaishaGaGroup, #CapitalPolicy, #JapanStocks","jir_key_figures":"Share acquisition cost: 44,776 million yen\nNumber of new shares issued: 9,974,291 shares\nFundraising amount: 26,770,997,044 yen","jir_meta_title":"\u3010Kabusikigaisha Ga Group\u3011Full Subsidiarization of Ayumi Pharmaceutical | June 2026","jir_meta_description":"Kabusikigaisha Ga Group will acquire all shares of Ayumi Pharmaceutical Holdings and execute a capital partnership in June 2026. With approximately 4.7 billion yen of capital infusion and new share issuance, this is a key capital policy for business expansion.","jir_og_title":"\u3010Kabusikigaisha Ga Group\u3011Subsidiarization of Ayumi Pharmaceutical and Capital Partnership | June 2026","jir_og_description":"Kabusikigaisha Ga Group completed the acquisition of all shares of Ayumi Pharmaceutical and entered a capital partnership in June 2026. About 4.7 billion yen of capital injection and new share issuance will promote long-term growth.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-61921","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n